Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
31 - 40 of 101
- Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease(2021)
Authors: Anne-Sophie Van Rompuy, Els Van Nieuwenhuysen, Ignace Vergote, Sileny Han
Pages: 95 - 99 - Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort(2021)
Authors: Hans Wildiers, Kevin Punie, Benoit Beuselinck, Paul Clement, Sileny Han, Els Van Nieuwenhuysen, Ignace Vergote, Ann Smeets, Ines Nevelsteen, Beppe Floris, et al.
Pages: 1041 - 1048 - Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)(2020)
Authors: Els Van Nieuwenhuysen
Pages: 1997 - 2001 - Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants inBRCA1/2: A Review of Secondary Prevention Guidelines(2020)
Authors: Sileny Han, Els Van Nieuwenhuysen, Toon Van Gorp, Chantal Van Ongeval, Jeroen Dekervel, Wouter Everaerts, Hans Wildiers, Ines Nevelsteen, Patrick Neven, Dirk Timmerman, et al.
- Genetische veranderingen en mogelijke nieuw gerichte therapieën in niet-hooggradig sereus epitheliaal en niet-epitheliaal eierstokkanker(2020)
Authors: Els Van Nieuwenhuysen, Ignace Vergote, Diether Lambrechts
- Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models(2020)
Authors: Nina Maenhoudt, Ziga Jan, Ruben Heremans, Bram Boeckx, Florian Hermans, Ingrid Arijs, Els Van Nieuwenhuysen, Ignace Vergote, Anne-Sophie Van Rompuy, Diether Lambrechts, et al.
Pages: 717 - 729 - Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D(2020)
Authors: Stefan Timmerman, Anne-Sophie Van Rompuy, Toon Van Gorp, Isabelle Vanden Bempt, Hilde Brems, Els Van Nieuwenhuysen, Sileny Han, Patrick Neven, Annouschka Laenen, Ignace Vergote
Pages: 245 - 251 - Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy(2020)
Authors: Liselore Loverix, Els Van Nieuwenhuysen, Sileny Han, Toon Van Gorp, Ignace Vergote
Pages: 466 - 472 - Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies(2020)
Authors: Ignace Vergote, Els Van Nieuwenhuysen, Sileny Han
Pages: 308 - 314 - Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.(2019)
Authors: Laurence Slembrouck, Isabelle Vanden Bempt, Sara Vander Borght, Patrick Neven, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Kevin Punie, Els Van Nieuwenhuysen, Sileny Han, et al.
Pages: 1557 - 1565